Chronic administration of the glucagon-like peptide-1 analog, liraglutide, delays the onset of diabetes and lowers triglycerides in UCD-T2DM rats

Bethany P. Cummings, Kimber Stanhope, James L. Graham, Denis G. Baskin, Steven C. Griffen, Cecilia Nilsson, Anette Sams, Lotte B. Knudsen, Kirsten Raun, Peter J Havel

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

OBJECTIVE - The efficacy of liraglutide, a human glucagon-like peptide-1 (GLP-1) analog, to prevent or delay diabetes in UCD-T2DM rats, a model of polygenic obese type 2 diabetes, was investigated. RESEARCH DESIGN AND METHODS - At 2 months of age, male rats were divided into three groups: control, food-restricted, and liraglutide. Animals received liraglutide (0.2 mg/kg s.c.) or vehicle injections twice daily. Restricted rats were food restricted to equalize body weights to liraglutide-treated rats. Half of the animals were followed until diabetes onset, whereas the other half of the animals were killed at 6.5 months of age for tissue collection. RESULTS - Before diabetes onset energy intake, body weight, adiposity, and liver triglyceride content were higher in control animals compared with restricted and liraglutide-treated rats. Energy-restricted animals had lower food intake than liraglutide-treated animals to maintain the same body weights, suggesting that liraglutide increases energy expenditure. Liraglutide treatment delayed diabetes onset by 4.1 ± 0.8 months compared with control (P < 0.0001) and by 1.3 ± 0.8 months compared with restricted animals (P < 0.05). Up to 6 months of age, energy restriction and liraglutide treatment lowered fasting plasma glucose and A1C concentrations compared with control animals. In contrast, liraglutide-treated animals exhibited lower fasting plasma insulin, glucagon, and triglycerides compared with both control and restricted animals. Furthermore, energy-restricted and liraglutide-treated animals exhibited more normal islet morphology. CONCLUSIONS - Liraglutide treatment delays the development of diabetes in UCD-T2DM rats by reducing energy intake and body weight, and by improving insulin sensitivity, improving lipid profiles, and maintaining islet morphology.

Original languageEnglish (US)
Pages (from-to)2653-2661
Number of pages9
JournalDiabetes
Volume59
Issue number10
DOIs
StatePublished - Oct 2010

Fingerprint

Glucagon-Like Peptide 1
Triglycerides
Body Weight
Energy Intake
Liraglutide
Fasting
Food
Adiposity
Glucagon
Type 2 Diabetes Mellitus
Energy Metabolism
Insulin Resistance
Research Design
Therapeutics
Eating

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Chronic administration of the glucagon-like peptide-1 analog, liraglutide, delays the onset of diabetes and lowers triglycerides in UCD-T2DM rats. / Cummings, Bethany P.; Stanhope, Kimber; Graham, James L.; Baskin, Denis G.; Griffen, Steven C.; Nilsson, Cecilia; Sams, Anette; Knudsen, Lotte B.; Raun, Kirsten; Havel, Peter J.

In: Diabetes, Vol. 59, No. 10, 10.2010, p. 2653-2661.

Research output: Contribution to journalArticle

Cummings, BP, Stanhope, K, Graham, JL, Baskin, DG, Griffen, SC, Nilsson, C, Sams, A, Knudsen, LB, Raun, K & Havel, PJ 2010, 'Chronic administration of the glucagon-like peptide-1 analog, liraglutide, delays the onset of diabetes and lowers triglycerides in UCD-T2DM rats', Diabetes, vol. 59, no. 10, pp. 2653-2661. https://doi.org/10.2337/db09-1564
Cummings, Bethany P. ; Stanhope, Kimber ; Graham, James L. ; Baskin, Denis G. ; Griffen, Steven C. ; Nilsson, Cecilia ; Sams, Anette ; Knudsen, Lotte B. ; Raun, Kirsten ; Havel, Peter J. / Chronic administration of the glucagon-like peptide-1 analog, liraglutide, delays the onset of diabetes and lowers triglycerides in UCD-T2DM rats. In: Diabetes. 2010 ; Vol. 59, No. 10. pp. 2653-2661.
@article{e858468e5a834f34883661b53064f7e5,
title = "Chronic administration of the glucagon-like peptide-1 analog, liraglutide, delays the onset of diabetes and lowers triglycerides in UCD-T2DM rats",
abstract = "OBJECTIVE - The efficacy of liraglutide, a human glucagon-like peptide-1 (GLP-1) analog, to prevent or delay diabetes in UCD-T2DM rats, a model of polygenic obese type 2 diabetes, was investigated. RESEARCH DESIGN AND METHODS - At 2 months of age, male rats were divided into three groups: control, food-restricted, and liraglutide. Animals received liraglutide (0.2 mg/kg s.c.) or vehicle injections twice daily. Restricted rats were food restricted to equalize body weights to liraglutide-treated rats. Half of the animals were followed until diabetes onset, whereas the other half of the animals were killed at 6.5 months of age for tissue collection. RESULTS - Before diabetes onset energy intake, body weight, adiposity, and liver triglyceride content were higher in control animals compared with restricted and liraglutide-treated rats. Energy-restricted animals had lower food intake than liraglutide-treated animals to maintain the same body weights, suggesting that liraglutide increases energy expenditure. Liraglutide treatment delayed diabetes onset by 4.1 ± 0.8 months compared with control (P < 0.0001) and by 1.3 ± 0.8 months compared with restricted animals (P < 0.05). Up to 6 months of age, energy restriction and liraglutide treatment lowered fasting plasma glucose and A1C concentrations compared with control animals. In contrast, liraglutide-treated animals exhibited lower fasting plasma insulin, glucagon, and triglycerides compared with both control and restricted animals. Furthermore, energy-restricted and liraglutide-treated animals exhibited more normal islet morphology. CONCLUSIONS - Liraglutide treatment delays the development of diabetes in UCD-T2DM rats by reducing energy intake and body weight, and by improving insulin sensitivity, improving lipid profiles, and maintaining islet morphology.",
author = "Cummings, {Bethany P.} and Kimber Stanhope and Graham, {James L.} and Baskin, {Denis G.} and Griffen, {Steven C.} and Cecilia Nilsson and Anette Sams and Knudsen, {Lotte B.} and Kirsten Raun and Havel, {Peter J}",
year = "2010",
month = "10",
doi = "10.2337/db09-1564",
language = "English (US)",
volume = "59",
pages = "2653--2661",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "10",

}

TY - JOUR

T1 - Chronic administration of the glucagon-like peptide-1 analog, liraglutide, delays the onset of diabetes and lowers triglycerides in UCD-T2DM rats

AU - Cummings, Bethany P.

AU - Stanhope, Kimber

AU - Graham, James L.

AU - Baskin, Denis G.

AU - Griffen, Steven C.

AU - Nilsson, Cecilia

AU - Sams, Anette

AU - Knudsen, Lotte B.

AU - Raun, Kirsten

AU - Havel, Peter J

PY - 2010/10

Y1 - 2010/10

N2 - OBJECTIVE - The efficacy of liraglutide, a human glucagon-like peptide-1 (GLP-1) analog, to prevent or delay diabetes in UCD-T2DM rats, a model of polygenic obese type 2 diabetes, was investigated. RESEARCH DESIGN AND METHODS - At 2 months of age, male rats were divided into three groups: control, food-restricted, and liraglutide. Animals received liraglutide (0.2 mg/kg s.c.) or vehicle injections twice daily. Restricted rats were food restricted to equalize body weights to liraglutide-treated rats. Half of the animals were followed until diabetes onset, whereas the other half of the animals were killed at 6.5 months of age for tissue collection. RESULTS - Before diabetes onset energy intake, body weight, adiposity, and liver triglyceride content were higher in control animals compared with restricted and liraglutide-treated rats. Energy-restricted animals had lower food intake than liraglutide-treated animals to maintain the same body weights, suggesting that liraglutide increases energy expenditure. Liraglutide treatment delayed diabetes onset by 4.1 ± 0.8 months compared with control (P < 0.0001) and by 1.3 ± 0.8 months compared with restricted animals (P < 0.05). Up to 6 months of age, energy restriction and liraglutide treatment lowered fasting plasma glucose and A1C concentrations compared with control animals. In contrast, liraglutide-treated animals exhibited lower fasting plasma insulin, glucagon, and triglycerides compared with both control and restricted animals. Furthermore, energy-restricted and liraglutide-treated animals exhibited more normal islet morphology. CONCLUSIONS - Liraglutide treatment delays the development of diabetes in UCD-T2DM rats by reducing energy intake and body weight, and by improving insulin sensitivity, improving lipid profiles, and maintaining islet morphology.

AB - OBJECTIVE - The efficacy of liraglutide, a human glucagon-like peptide-1 (GLP-1) analog, to prevent or delay diabetes in UCD-T2DM rats, a model of polygenic obese type 2 diabetes, was investigated. RESEARCH DESIGN AND METHODS - At 2 months of age, male rats were divided into three groups: control, food-restricted, and liraglutide. Animals received liraglutide (0.2 mg/kg s.c.) or vehicle injections twice daily. Restricted rats were food restricted to equalize body weights to liraglutide-treated rats. Half of the animals were followed until diabetes onset, whereas the other half of the animals were killed at 6.5 months of age for tissue collection. RESULTS - Before diabetes onset energy intake, body weight, adiposity, and liver triglyceride content were higher in control animals compared with restricted and liraglutide-treated rats. Energy-restricted animals had lower food intake than liraglutide-treated animals to maintain the same body weights, suggesting that liraglutide increases energy expenditure. Liraglutide treatment delayed diabetes onset by 4.1 ± 0.8 months compared with control (P < 0.0001) and by 1.3 ± 0.8 months compared with restricted animals (P < 0.05). Up to 6 months of age, energy restriction and liraglutide treatment lowered fasting plasma glucose and A1C concentrations compared with control animals. In contrast, liraglutide-treated animals exhibited lower fasting plasma insulin, glucagon, and triglycerides compared with both control and restricted animals. Furthermore, energy-restricted and liraglutide-treated animals exhibited more normal islet morphology. CONCLUSIONS - Liraglutide treatment delays the development of diabetes in UCD-T2DM rats by reducing energy intake and body weight, and by improving insulin sensitivity, improving lipid profiles, and maintaining islet morphology.

UR - http://www.scopus.com/inward/record.url?scp=77957608672&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957608672&partnerID=8YFLogxK

U2 - 10.2337/db09-1564

DO - 10.2337/db09-1564

M3 - Article

VL - 59

SP - 2653

EP - 2661

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 10

ER -